This job has expired

You will need to login before you can apply for a job.

SRA – Scientist II, Purification / Analytical Chemistry

Nurix Therapeutics
The Woodlands, TX
Start date
May 26, 2023

Job Details

We are seeking a highly motivated individual to establish and operate a small-molecule purification lab. This position will perform purifications of small molecule libraries as well as individual compounds on mg to multi-gram scale by mass directed HPLC in support of Nurix’s early drug discovery efforts. The role requires the ability to develop custom purification methods using state of the art analytical and preparative scale equipment. 

This role also requires hands on experience in maintenance and troubleshooting of chromatography instrumentation.

The candidate should have a strong desire to learn new techniques, stay up to date with purification trends and interest to cross train team members. The ideal candidate will be self-driven, resourceful, very organized and focused, and enjoy working in the dynamic team environment here at Nurix.

Required Qualifications

Minimum qualifications include a B.S. or equivalent degree in chemistry, analytical chemistry or related field, with (8+) years of industrial experience, or a master’s degree in chemistry, biochemistry or a related field with (5+) years of industrial experience in purification of small molecules.

Bonus Qualifications

Experience with data management and digital workflows (LIMS or cloud databases)


Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels.

Nurix’s wholly owned pipeline comprises targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.

Find Us
1700 Owens Street
Suite 205
San Francisco

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert